The estimated Net Worth of A Brian Davis is at least $1.36 Million dollars as of 4 June 2021. Mr. Davis owns over 5,000 units of Verrica Pharmaceuticals Inc stock worth over $24,897 and over the last 7 years he sold VRCA stock worth over $0. In addition, he makes $1,339,580 as Chief Financial Officer at Verrica Pharmaceuticals Inc.
Brian has made over 2 trades of the Verrica Pharmaceuticals Inc stock since 2020, according to the Form 4 filled with the SEC. Most recently he bought 5,000 units of VRCA stock worth $49,450 on 4 June 2021.
The largest trade he's ever made was buying 7,900 units of Verrica Pharmaceuticals Inc stock on 13 August 2020 worth over $49,296. On average, Brian trades about 1,433 units every 33 days since 2018. As of 4 June 2021 he still owns at least 12,900 units of Verrica Pharmaceuticals Inc stock.
You can see the complete history of Mr. Davis stock trades at the bottom of the page.
Brian Davis serves as Chief Financial Officer of the Company. Prior to joining our company, Mr. Davis, was the Chief Financial Officer of Strongbridge Biopharma plc, a public commercial-stage biopharmaceutical company, from March 2015 to September 2019. Prior to joining Strongbridge, Mr. Davis served as Senior Vice President and Chief Financial Officer at Tengion, Inc., a publicly traded regenerative medicine company, from 2010 to 2014. In 2014, Tengion, Inc. filed a petition for relief under Chapter 7 of Title 11 of the United States Bankruptcy Code. From 2009 to 2010, Mr. Davis served in a consulting capacity as Chief Financial Officer of Neose Technologies, Inc., a biopharmaceutical company. Mr. Davis worked at Neose Technologies, Inc. from 1994 to 2009, where he held several positions of increasing responsibility, including Senior Vice President and Chief Financial Officer. Mr. Davis is licensed as a certified public accountant and received a B.S. in accounting from Trenton State College and an M.B.A. from The Wharton School at the University of Pennsylvania.
As the Chief Financial Officer of Verrica Pharmaceuticals Inc, the total compensation of Brian Davis at Verrica Pharmaceuticals Inc is $1,339,580. There are 1 executives at Verrica Pharmaceuticals Inc getting paid more, with Ted White having the highest compensation of $1,441,190.
Brian Davis is 52, he's been the Chief Financial Officer of Verrica Pharmaceuticals Inc since 2019. There are 9 older and 5 younger executives at Verrica Pharmaceuticals Inc. The oldest executive at Verrica Pharmaceuticals Inc is Lawrence Eichenfield, 62, who is the Director.
A's mailing address filed with the SEC is 103 CARNEGIE CENTER, SUITE 300, PRINCETON, NJ, 08540.
Over the last 6 years, insiders at Verrica Pharmaceuticals Inc have traded over $8,200,904 worth of Verrica Pharmaceuticals Inc stock and bought 11,305,854 units worth $62,586,502 . The most active insiders traders include Advisors Llcperceptive Life..., Paul B Manning, and John A Iii Stalfort. On average, Verrica Pharmaceuticals Inc executives and independent directors trade stock every 20 days with the average trade being worth of $213,456. The most recent stock trade was executed by Christopher G. Hayes on 26 August 2024, trading 35,713 units of VRCA stock currently worth $93,211.
verrica pharmaceuticals inc., a clinical stage medical dermatology company, develops and commercializes dermatological treatments in the united states. the company's lead product candidate include vp-102 that is in phase iii clinical trial for the treatment of molluscum contagiosum; in phase ii clinical trial for the treatment of common warts; and completed phase i clinical trial for the treatment of genital warts. it is also developing cantharidin-based product candidate, vp-103 for the treatment of plantar warts. the company has a license agreement with lytix biopharma as to develop and commercialize ltx-315 for dermatologic oncology indications. verrica pharmaceuticals inc. was founded in 2013 and is headquartered in west chester, pennsylvania.
Verrica Pharmaceuticals Inc executives and other stock owners filed with the SEC include: